

## Performance as at 30<sup>th</sup> June 2021

	1m	6m	1yr	3yr p.a.	Inception p.a.#
<b>Fund ^</b>	<b>4.8%</b>	<b>15.1%</b>	<b>55.1%</b>	<b>12.0%</b>	<b>12.9%</b>
<i>Benchmark*</i>	3.1%	10.8%	33.2%	8.6%	10.2%
Value added	1.7%	4.3%	21.8%	3.4%	2.7%

^ Spheria Australian Smaller Companies Fund. Returns of the Fund are net of applicable fees, costs and taxes. All p.a. returns are annualised.

\* Benchmark is the S&P/ASX Small Ordinaries Accumulation Index.

# Inception date of the current investment strategy is 11<sup>th</sup> July 2016. The Fund was established in June 2005. Past performance is not a reliable indicator of future performance.

## Top 5 Holdings

Company Name	% Portfolio
Adbri Limited	4.9
Fletcher Building	4.6
Healuis	4.0
Bega Cheese Ltd	3.5
Iress Limited	3.4
<b>Top 5</b>	<b>20.4</b>

Source: Spheria Asset Management

## Commentary

The Spheria Australian Smaller Companies Fund returned 4.8% (after fees) in June, outperforming the benchmark by 1.7%. Over the quarter to the end of June, the Fund rose 8.4%, slightly underperforming the benchmark by 0.1%.

### Markets


Markets locally rose over June with strong returns in particular in a narrow subset of high momentum technology names and in materials names exposed to popular thematic (e.g., lithium, mineral sands) and to coal following strong price rises in both coking and thermal coal. Gold fell 7% over the month with equity exposures similarly coming under pressure. Despite the benchmark WTI price rising almost 10% over the month oil and gas names were mixed. Several technology stocks made record absolute highs and re-rated to record EV/Sales multiples despite no material newsflow. These included Pro Medicus (PME.ASX), Megaport (MP1.ASX), Realestate.com.au (REA.ASX) and Seek (SEK.ASX).

Most re-opening trades were neutral to down for the month following the emergence of the delta strain in the U.K. (originally responsible for the second wave in India) which has seen a strong resurgence of cases (mostly amongst children and young adults and the unvaccinated), albeit with a much less pronounced rise in hospitalisations and no material increase in deaths. Locally we observed some strong negative share price reactions to weaker than expected earnings forecasts e.g., Nuix (NXL.ASX) and Integrated Research (IRI.ASX) or other negative newsflow, e.g., Nuix (NXL.ASX) on management resignations and ASIC investigations and Genworth (GMA.ASX) following the Commonwealth Bank (CBA.ASX) announcing it will put to tender its lender's mortgage insurance volumes that currently go to Genworth. Corporate activity was elevated over the month with Altium (ALU.ASX) rejecting a proposal from Autodesk of the U.S., Isentia (ISD.ASX) receiving a recommended bid at a 154% premium to the last price, Reckon (RKN.ASX) having 19.9% of its shares acquired by Novatti (NOV.ASX) and the media reporting that IRESS (IRE.ASX) was the subject of a failed raid on its register during the month.

The Fund outperformed due to an overweight to small and microcap gaming, media and retail exposures, the sale of its holding in Isentia (ISD.ASX at a 154% premium to last) and newsflow that portfolio holding


**Continued on the next page...**

## Market Cap Bands



Source: Spheria Asset Management

## Active Sector Exposure



Source: Spheria Asset Management

IRESS was the recipient of a failed raid at a substantial premium to last. The underweight to gold also contributed to performance.

Despite our recent outperformance we continue to observe and remain concerned about speculative excess in high momentum names although we have noted a narrowing of the field of names that continue to re-rate as some former highflyers have come down to earth following disappointing newsflow. While some COVID-19 beneficiaries in the e-Commerce, Fintech and Biotech space have de-rated (albeit in most cases to levels that are still well above our measure of value), these appear to have largely been replaced by cohorts of stocks within the materials space that are seeing price action that is difficult to justify. In particular, those companies exposed to popular thematic (e.g., battery materials and rare earths) appear to be capitalising near record high prices and enormous margins well out into the future - far beyond time horizons that one can credibly forecast and in some cases in direct opposition to the likely impact on supply and demand caused by current trends (i.e., expensive share prices equals a low cost of capital for new supply in these materials).

Given the significant rise of passive, quantitative and direct retail investors in the market and the unprecedented liquidity that Central Banks have injected into the financial system we should perhaps not be surprised that valuation disparities are at levels not seen since the dot.com boom and that price momentum can push valuations to extreme levels. We are trying to remain disciplined and weight the portfolio towards more 'boring' and relatively unpopular names with proven, high returning, cash generative business models that remain at multiples below their historical relative trading ranges. Given rising inflation (both measured inflation and inflation expectations) that is being generated by high levels of fiscal and monetary stimulus alongside shortages of raw materials and certain intermediary goods (e.g., silicon chips) we are mindful of purchasing companies with pricing power that should be better placed to maintain margins in an inflationary environment. If Central Banks eventually take the punchbowl away (or at least stop spiking it with vodka) we are hopeful that our focus on purchasing undervalued securities should impact us less than the market more broadly which is currently paying extreme multiples for firms that are **forecast** to have strong outer year growth. In the meantime, the high levels of liquidity appear to be feeding an M&A cycle that should support our returns given our focus on buying undervalued, cash generative businesses with underleveraged balance sheets means our portfolio companies are more often the target of this activity than the average index constituent.

## Major Contributors for the Month

**Ainsworth (AGI.ASX)** was the largest contributor as the manufacturer of gaming machines rallied another 27% to end the financial year up 349% from the nadir it hit in mid-November. Whilst the pandemic has significantly negatively impact Ainsworth's operations the firm has never been in danger of insolvency given property holdings in the U.S. that at one point exceeded its market capitalisation. The end market of casinos, pubs and clubs in its two major markets of Australia and the United States have recovered strongly and in many cases are now in a position to recommence expenditure on new machines. As a result, the group returned to profitability in the 2H of the financial year. New management in our view has made sensible changes to personnel to improve the product development cycle which we feel have been obscured by the pandemic. We still see potential for Ainsworth to leverage its valuable portfolio of intellectual property and regulatory approval to improve earnings well above the level it was generating prior to COVID-19.

**IRESS (IRE.ASX)** was the next largest contributor after rallying 21% on news that the firm had been the subject of a failed raid by an investment bank at a substantial premium to the last price on behalf of a financial investor. While the market has been frustrated by the lack of EPS growth in IRESS over the last several years we believe the investment in capability across their product suite has positioned them well strategically for future growth and hence are not surprised it has attracted corporate attention.

**Seven West Media (SWM.ASX)** contributed to attribution given the company's 16% return over the month on the back of a stronger than expected earnings update and better than expected net debt reduction. Seven West Media

*Continued on the next page...*

continues to screen extremely cheaply with an EV/EBIT of c4x despite a subset of the earnings coming from activities that would normally attract very high multiples (e.g., transmission towers and the production studio). With net debt now well under control (less than 1x EBITDA) we feel confident there remains significant returns to be derived from this position.

## Major Detractors for the Month

**Geopacific Resources (GPR.ASX)** was the largest detractor as it retraced almost 15% despite finalising its project funding facility with Sprott for the development of its Woodlark Island project and declaring final investment decision now that the project is fully funded to completion. We believe tax loss selling played a major part in this price action with the stock up 12% since the June financial year end. We still see Geopacific as incredibly undervalued trading at a market capitalisation of less than \$180m despite \$143m of cash as at March 31, 2021 and having spent \$33m on the project. This effectively implies a net present value of zero for the project despite a robust bankable feasibility study that generates a post-tax NPV8 of A\$347m at a A\$2,200 gold price (vs. spot of A\$2,400). We also see scope to add materially to this base case given strong in pit, extensional and regional exploration potential and our view that the conservative assumption around mining dilution (30%) on the orebody is likely to lead to positive reconciliation once the project commences production during the second half of 2022.

**Pro Medicus (PME.ASX – not owned)** detracted as the stock rallied 27% on no material news to close the month at an EV of over \$6 billion for a company with an annualised run rate of revenue somewhere in the mid \$60m mark. While we view PME.ASX as a very high-quality company we feel the market is being far too generous in its valuation of the firm, particularly given the regular material share sales by insiders.

**Genworth (GMA.ASX)** detracted as the monoline provider of lender's mortgage insurance fell 20% following the announcement that its largest customer Commonwealth Bank (CBA.ASX) intends to tender its volumes from the end of December 2022 (the end of the current exclusivity period). While not good news given CBA.ASX accounts for more than 50% of Genworth's gross written premiums per annum, we believe the share price fall is an overreaction. Firstly, there is a good chance that CBA.ASX recontract with Genworth given the significant integration of systems that exist between the two which allows CBA.ASX to rapidly get LMI volumes sent to Genworth approved (and hence keep its market leading response rates). Secondly, CBA.ASX as the largest customer will have the sharpest pricing of Genworth's 50+ bank and non-bank customers and therefore the lowest profitability (and ROE). Thirdly, the stock now trades at a 32% discount to net tangible assets (which is already conservatively stated given provisioning taken early on during COVID-19 has proven to be far too high as unemployment has been much lower than expected and home price growth much higher). Were Genworth to lose this volume it would allow a substantial amount of regulatory capital to be returned to shareholders either through dividends or buybacks. Finally, the last major transaction in the space (the sale of Westpac's internal LMI book) was undertaken at NTA.

## Outlook & Strategy

We continue to believe that the interests of our investors are best served by staying true to our investment philosophy of buying cash generative business models, with a demonstrated track record of solid returns and at a sensible valuation given their industry dynamics and positioning. While the emergence and spread of variants of COVID-19 with greater transmissibility and in some cases the ability to evade vaccines (especially sterilising immunity as opposed to the prevention of hospitalisation or deaths) is likely to cause volatility, the evidence overseas suggests the current crop of vaccines have firmly broken the once firm link between rising cases and hospitalisations and deaths. We continue to place an informed bet on the ingenuity of humankind to conquer this challenge. The rising specter of inflation and some emerging signs of a reluctance by Central Banks to pump prime to the same extent as they have since the emergence of COVID-19 means we are focusing our efforts on finding business models with pricing power and trying to avoid those that are likely to see unexpected compression in margins (e.g., mining contractors). The market continues to be conducive to high levels of corporate activity given plentiful liquidity, procyclical boards and record levels of private equity dry powder. We anticipate we may be the

*Continued on the next page...*

beneficiaries of future activity given our predilection for undervalued, cash generative businesses with modestly or underleveraged balance sheets. Pleasingly we continue to be presented with opportunities for rotation into new names with strong fundamental valuation support as Mr Market's attention waxes and wanes in different names. The market remains highly bifurcated amid concerning signs of speculative excess in concept stocks and those leveraged to popular thematic. We continue to avoid these overvalued names and instead try to maximise the risk reward equation for investors with a disciplined investment approach strongly guided by valuation fundamentals.

	Spheria Australian Smaller Companies Fund	Platform availability
Benchmark (universe)	S&P/ASX Small Ordinaries Accumulation Index	ASGARD
Investment objective	The Fund aims to outperform the S&P/ASX Small Ordinaries Accumulation Index over the medium to long term.	BT Panorama
Investing universe	Primarily listed companies outside the top 100 ASX listed companies by market capitalisation and companies listed on the New Zealand Stock Exchange with an equivalent market capitalisation	BT Wrap
Distributions	Half yearly	First Wrap
Fees	1.10% p.a. management fee & 20% performance fee of the Fund's excess return versus its benchmark, net of the management fee.	HUB24
Cash	<ul style="list-style-type: none"> <li>Up to 20% cash</li> <li>Typically 5% - 10%</li> </ul>	IOOF Portfolio Service
Expected turnover	30-40%	Macquarie Wrap
Style	Long only	mFund
APIR	WHT0008AU	MLC Wrap / Navigator
Minimum Investment	\$25,000	Netwealth
		One Vue
		uXchange

This communication has been prepared by Spheria Asset Management Pty Limited ABN 42 611 081 326 ('Spheria'), Corporate Authorised Representative 1240979 of Pinnacle Investment Management Limited (AFSL 322140). Interests in the Spheria Australian Smaller Companies Fund ARSN 117 083 762 (the 'Fund') are issued by Pinnacle Fund Services Limited (ABN 29 082 494 362 AFSL 238371), the Responsible Entity. The Responsible Entity is not licensed to provide financial product advice. You should consider the Product Disclosure Statement ('PDS') in its entirety before making an investment decision. The current PDS of the Fund can be found at [www.spheria.com.au/funds](http://www.spheria.com.au/funds). Spheria is the investment manager of the Fund.

Spheria and Pinnacle Fund Services Limited believe the information contained in this communication is reliable, however, no warranty is given as to its accuracy and persons relying on this information do so at their own risk. To the extent permitted by law, Spheria and Pinnacle Fund Services Limited disclaim all liability to any person relying on the information in respect of any loss or damage (including consequential loss or damage) however caused, which may be suffered or arise directly or indirectly in respect of such information contained in this communication. This communication is for general information only. The information is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. It has been prepared without taking account of any person's objectives, financial situation or needs. Any person considering action on the basis of this communication must seek individual advice relevant to their particular circumstances and investment objectives.

Any opinions or forecasts reflect the judgment and assumptions of Spheria on the basis of information at the date of publication and may later change without notice. Any projections are estimates only and are contingent upon matters outside the control of Spheria and therefore may not be realised in the future. Past performance is not a reliable indicator of future performance.

The information contained in this communication is not to be disclosed in whole or part or used by any other party without the prior written consent of Spheria.